BACKGROUND:Pulmonary hypertension (PH) is associated with restricted physical capacity, limited quality of life, and a poor prognosis because of right heart failure. The present study is the first prospective randomized study to evaluate the effects of exercise and respiratory training in patients with severe symptomatic PH. METHODS AND RESULTS:Thirty patients with PH (21 women; mean age, 50+/-13 years; mean pulmonary artery pressure, 50+/-15 mm Hg; mean World Health Organization [WHO] class, 2.9+/-0.5; pulmonary arterial hypertension, n=23; chronic thromboembolic PH, n=7) on stable disease-targeted medication were randomly assigned to a control (n=15) and a primary training (n=15) group. Medication remained unchanged during the study period. Primary end points were the changes from baseline to week 15 in the distance walked in 6 minutes and in scores of the Short Form Health Survey quality-of-life questionnaire. Changes in WHO functional class, Borg scale, and parameters of echocardiography and gas exchange also were assessed. At week 15, patients in the primary and secondary training groups had an improved 6-minute walking distance; the mean difference between the control and the primary training group was 111 m (95% confidence interval, 65 to 139 m; P<0.001). Exercise training was well tolerated and improved scores of quality of life, WHO functional class, peak oxygen consumption, oxygen consumption at the anaerobic threshold, and achieved workload. Systolic pulmonary artery pressure values at rest did not change significantly after 15 weeks of exercise and respiratory training (from 61+/-18 to 54+/-18 mm Hg) within the training group. CONCLUSIONS: This study indicates that respiratory and physical training could be a promising adjunct to medical treatment in severe PH. The effects add to the beneficial results of modern medical treatment.
RCT Entities:
BACKGROUND:Pulmonary hypertension (PH) is associated with restricted physical capacity, limited quality of life, and a poor prognosis because of right heart failure. The present study is the first prospective randomized study to evaluate the effects of exercise and respiratory training in patients with severe symptomatic PH. METHODS AND RESULTS: Thirty patients with PH (21 women; mean age, 50+/-13 years; mean pulmonary artery pressure, 50+/-15 mm Hg; mean World Health Organization [WHO] class, 2.9+/-0.5; pulmonary arterial hypertension, n=23; chronic thromboembolic PH, n=7) on stable disease-targeted medication were randomly assigned to a control (n=15) and a primary training (n=15) group. Medication remained unchanged during the study period. Primary end points were the changes from baseline to week 15 in the distance walked in 6 minutes and in scores of the Short Form Health Survey quality-of-life questionnaire. Changes in WHO functional class, Borg scale, and parameters of echocardiography and gas exchange also were assessed. At week 15, patients in the primary and secondary training groups had an improved 6-minute walking distance; the mean difference between the control and the primary training group was 111 m (95% confidence interval, 65 to 139 m; P<0.001). Exercise training was well tolerated and improved scores of quality of life, WHO functional class, peak oxygen consumption, oxygen consumption at the anaerobic threshold, and achieved workload. Systolic pulmonary artery pressure values at rest did not change significantly after 15 weeks of exercise and respiratory training (from 61+/-18 to 54+/-18 mm Hg) within the training group. CONCLUSIONS: This study indicates that respiratory and physical training could be a promising adjunct to medical treatment in severe PH. The effects add to the beneficial results of modern medical treatment.
Authors: Carrie P Aaron; Harikrishna Tandri; R Graham Barr; W Craig Johnson; Emilia Bagiella; Harjit Chahal; Aditya Jain; Jorge R Kizer; Alain G Bertoni; João A C Lima; David A Bluemke; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2010-09-02 Impact factor: 21.405
Authors: Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes Journal: J Heart Lung Transplant Date: 2011-04-13 Impact factor: 10.247
Authors: Horst Olschewski; M M Hoeper; M M Borst; R Ewert; E Grünig; F-X Kleber; B Kopp; C Opitz; F Reichenberger; A Schmeisser; D Schranz; I Schulze-Neick; H Wilkens; J Winkler; H Worth Journal: Clin Res Cardiol Date: 2007-05 Impact factor: 5.460
Authors: R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle Journal: Eur Respir J Date: 2008-12-01 Impact factor: 16.671
Authors: John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405